Alexion sales and marketing update

The U.K.’s NICE issued draft guidance recommending the use of Strensiq asfotase alfa from Alexion under a managed access agreement to treat the bone manifestations of perinatal- and infantile-onset hypophosphatasia (HPP). The recommendation covers patients whose onset of the disease occurs before six months of age and is contingent on Alexion providing Strensiq under a discount scheme, which includes an undisclosed maximum cost cap per patient.

According to NICE, its cost varies from L165,000 ($215,457) for a baby to L1.5 million ($2 million) for an 80 kg adult, based on its list price. ...